GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (FRA:UKJ) » Definitions » Short-Term Debt

Opthea (FRA:UKJ) Short-Term Debt : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Opthea Short-Term Debt?

Opthea's Short-Term Debt for the quarter that ended in Dec. 2023 was €0.00 Mil.

Opthea Short-Term Debt Historical Data

The historical data trend for Opthea's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Short-Term Debt Chart

Opthea Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Opthea Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Opthea Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Opthea Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Opthea's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Opthea (FRA:UKJ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (FRA:UKJ) » Definitions » Short-Term Debt
Comparable Companies
ASX:PYC ASX:BOT ASX:IMM ASX:IMU ASX:RAC ASX:DXB ASX:PIQ ASX:RCE ASX:ALA ASX:PAA OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
OPT:USA OPT:Australia
Address
650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141
Website
https://www.opthea.com
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

Opthea (FRA:UKJ) Headlines

No Headlines